• In the current study, researchers retrospectively assessed the clinical outcomes of 45 breast cancer patients receiving stereotactic radiosurgery (SRS) for 72 brain metastases.
• The median number of brain metastases treated was 2, with a range of 1 to 20. The median OS dating from BM diagnosis was 27.6 months and that from post-SRS was 18.5 months. The one-year survival rate after BM diagnosis was 55% and the two-year survival rate was 41%, with the Luminal-B-human-epidermal-growth-receptor-positive (HER2 ) subtype exhibiting the longest median OS of 39.1 months. Factors contributing to the longest OS included grade 2, craniotomy, and two or more systemic therapies administered. On the other hand, age less than 50 years, grade 3, HER2 , and whether the brain as the first metastatic site all contributed to a higher risk of intracranial recurrence.
• “We acknowledge downsides to our study, which might have influenced our results: retrospective data collection, small and unbalanced sample size, and not all medical charts were fully available at the time of study data collection,” the authors wrote. “Furthermore, we did not systematically assess the neurological outcomes of our patients, which would improve the reporting of the treatment outcomes. However, our results, especially regarding improved OS rates, imply the cautious selection of BC patients throughout the observation period. In the future, multicentric prospective studies are warranted to further explore the use of SRS in patients with BC.”
2021 Feb 25;26(1):1-11. doi: 10.5603/RPOR.a2021.0001. 1 Division of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. Free PMC article Ivica Ratosa et al. Rep Pract Oncol Radiother. Free PMC article . 2021 Feb 25;26(1):1-11. doi: 10.5603/RPOR.a2021.0001. 1 Division of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.